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Autism is a neurodevelopmental disorder marked by social skills and communication
deﬁcits and interfering repetitive behavior. Intellectual disability often accompanies autism.
In addition to behavioral deﬁcits, autism is characterized by neuropathology and brain
overgrowth. Increased intracranial volume often accompanies this brain growth. We have
found that the Alzheimer’s disease (AD) associated amyloid-β precursor protein (APP),
especially its neuroprotective processing product, secreted APP α, is elevated in persons
with autism.This has led to the “anabolic hypothesis” of autism etiology, in which neuronal
overgrowth in the brain results in interneuronal misconnections that may underlie multiple
autism symptoms. We review the contribution of research in brain volume and of APP to
the anabolic hypothesis, and relate APP to other proteins and pathways that have already
been directly associated with autism, such as fragile X mental retardation protein, Ras
small GTPase/extracellular signal-regulated kinase, and phosphoinositide 3 kinase/protein
kinase B/mammalian target of rapamycin.We also present additional evidence of magnetic
resonance imaging intracranial measurements in favor of the anabolic hypothesis. Finally,
since it appears that APP’s involvement in autism is part of a multi-partner network, we
extend this concept into the inherently interactive realm of epigenetics. We speculate
that the underlying molecular abnormalities that inﬂuence APP’s contribution to autism
are epigenetic markers overlaid onto potentially vulnerable gene sequences due to
environmental inﬂuence.
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BACKGROUND
Autism is a speciﬁc form of what is now termed autism
spectrum disorder (ASD). ASD is characterized by deﬁcits in
communication and social interaction and by stereotypic and
rigid behaviors. In addition, macrocephaly, cognitive impair-
ment, and seizures can be associated with ASD. Other brain
anatomical abnormalities in autism have been reported in the lit-
erature, along with differences in intracranial volumes (Aylward
et al., 1999, 2002; McCaffery and Deutsch, 2005). Pathologically,
macrocephaly due to brain enlargement in autism is likely due
Abbreviations: AD,Alzheimer’s disease; ADAM, a disintegrin and metallopro-
teinase; AICD, APP intracellular domain; APP, amyloid-β precursor protein;
ASD, autism spectrum of neurodevelopmental disorders; Aβ, amyloid-β peptide;
FMR1, fragile X mental retardation 1 gene; FMRP, fragile X mental retarda-
tion protein; FXS, Fragile X syndrome; FXTAS, fragile X-associated tremor/ataxia
syndrome; LEARn, latent early-life associated regulation; mGluR, metabotropic
glutamate receptor; MRI, magnetic resonance imaging; PI3K/mTOR, phospho-
inositide 3 kinase/mammalian target of rapamycin; PKC, protein kinase C;
PRKB1, protein kinase c-β1 gene; Ras/ERK, Ras small GTPase/extracellular
signal-regulated kinase; sAPPα, soluble APP α; TACE, tumor necrosis factor-
α converting enzyme; TIV, total intracranial volume; TNF-α, tumor necrosis
factor α.
to cell adhesion dysfunction. The amyloid-β precursor protein
(APP), which is better known in association with Alzheimer’s dis-
ease (AD), is a known cell adhesion and neurite pruning protein
(Thinakaran and Koo, 2008; Nikolaev et al., 2009). The amy-
loidogenic pathway favors loss of function APP with sequential
cleavage of APP by β-secretase (BACE1) resulting in neurotoxic
amyloid-β (Aβ) peptides 40 and 42, the major components of
cerebral amyloid plaques associated with brain atrophy found in
AD. Alternative cleavage via the α secretase non-amyloidogenic
pathway releases the non-amyloidogenic secreted APP α
(sAPPα; Hardy, 2009), believed to have neurotrophic properties
(Mattson, 1994; Ray et al., 2011). The expected plasma neuronal
marker proﬁle in AD is low sAPPα and high Aβ 40/42. The
non-amyloidogenic pathway (represented by high sAPPα and low
Aβ 40/42) may represent a gain of function toxicity associated
with neurodevelopmental conditions including autism. Of par-
ticular interest to autism research, we (Sokol et al., 2006; Ray
et al., 2011), and others (Bailey et al., 2008), have determined
that the cleavage product of APP, sAPPα, is elevated in plasma
from autistic subjects vs. neurotypical and mildly autistic subjects
(Ray et al., 2011).
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These elevated sAPPα levels and increased intracranial volumes
have led to the “anabolic hypothesis” of autism etiology:autism
as a product of overgrowth (or insufﬁcient pruning) of cra-
nial neurons, resulting in neurological and behavioral symptoms
(Figure 1). In addition to circumstantial evidence, speciﬁc APP
pathways support this hypothesis. Fragile X syndrome (FXS),
which is commonly marked by a comorbid diagnosis of ASD,
involves the disruption of normal interaction between the frag-
ile X mental retardation protein (FMRP) and metabotropic
glutamate receptor (mGluR) which misregulates APP mRNA
translation (Westmark and Malter, 2007). Of note, FXS has
been associated with macrocephaly (Laxova, 1994). APP and
metabolites also have a purported anabolic rolewithin other trans-
lation regulating pathways such as Ras small GTPase/extracellular
signal-regulated kinase (Ras/ERK; Venezia et al., 2006; Rohe
et al., 2008) and phosphoinositide 3 kinase/mammalian target
of rapamycin (P13K/mTOR; Rohe et al., 2008; Bhaskar et al.,
2009).
FIGURE 1 | Contrast of normal and pathogenic APP protein processing
pathways. (A) Normal pathway. APP protein (green) is processed by
secretases (violet) and usually cleaved at the α-secretase site by ADAM10 or
ADAM17 (α), then afterwards by the γ-secretase complex (γ). This produces
sAPPα, the non-pathogenic p3 peptide product, and the APP intracellular
domain (AICD). The sAPPα product is both neuroprotective and activates
microglia. These balanced processes, under normal conditions, lead to neural
pruning and normal development at appropriate times. This is the majority
APP processing pathway. (B) APP anabolic dysfunction of the α-secretase
pathway, speciﬁcally anabolic proteins/peptide levels, processes, and
outcomes indicated in yellow. Overproduction of APP and/or excess
α-secretase activity results in overproduction of sAPPα, which both activates
neuroglia and is neuroprotective. Neuroprotective activity would presumably
overwhelm microglial activation, since other molecules, presumably not
also over-produced in this scenario, also activate microglia during neural
pruning and would not be able to make up the difference to overwhelm
additional sAPPα neuroprotection. The net result would bring about
neuronal overgrowth and risk for autism. (C)The “catabolic”/
neurodegenerative amyloidogenic β-secretase pathway, speciﬁcally
catabolic protein/peptide levels, processes, and outcomes indicated in red.
This pathway is associated with neurodegeneration and Alzheimer’s disease.
Possible increase in APP protein and BACE1 protein levels (β) result in greater
cleavage at the β-secretase and then by γ-secretase complex (γ). This
produces sAPPβ, pathogenic/neurotoxic Aβ peptide, and AICD. sAPPβ
activates microglia without offering neuroprotection. Thus, two of the three
major products of the β-secretase pathway are neurodegenerative. If the
β-secretase pathway becomes excessive, risk for Alzheimer’s disease
increases.
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The anabolic hypothesis of autism etiology provides speciﬁc
molecular mechanisms for the development of ASD. Since the
hypothesis is based upon levels of gene expression/translation, it
has greater explanatorypower thangeneticmutationmodels. Like-
wise, recent years have seen greater recognition of environmental
inﬂuences on gene expression, such as the enviromic/epigenomic
latent early-life associated regulation (LEARn)model (Lahiri et al.,
2009). Genetic predisposition would be conditioned by envi-
ronmental risk to produce overall risk for autism and likewise
point to potential preventative and treatment methods based
on solid biochemical and neurological understanding of this
disorder.
AUTISM AS AN EARLY NEURODEVELOPMENTAL DISORDER
Autism is characterized by deﬁcits in communication and social
interaction and by stereotypic and rigid repetitive behaviors.
Prevalence of ASD in theUnited States is estimated to be between 1
in 50 (Blumberg et al., 2013) and 1 in 88 (AutismandDevelopmen-
talDisabilitiesMonitoringNetwork,2012). Diagnosis can bemade
reliably as early as ages 18–24 months, with symptoms of autism
seen as early as 9–12 months (Johnson and Myers, 2007). Infants
with autism often show delayed onset of babbling, decreased ges-
tures, imitation, and responsiveness within the ﬁrst year. In the
second and third years, there often is decreased frequency and
diversity of language, less “showing” and “pretend” behaviors and
reduced “joint attention,” considered a unique, core feature of
autism (Landa, 2007). One in four children with autism may
demonstrate word loss and other signs of communication regres-
sion during toddlerhood (Lord et al., 2004). Word loss stands out
as a “red ﬂag” and is considered unique to autism (Lord et al.,
2004). This early presentation of symptoms suggests an associated
prenatal/early childhood disruption of brain function that may
underlie symptoms.
APP IN EARLY BRAIN DEVELOPMENT
APP is a large (695–770 amino acid) glycoprotein produced in
brain microglia, astrocytes, oligodendrocytes, and neurons (Mul-
lan and Crawford, 1993). It has a large extracytoplasmic domain,
a membrane-spanning domain containing the Aβ-peptide, and
a short intracytoplasmic domain (Jolly-Tornetta et al., 1998).
MatureAPP is axonally transported and can be secreted from axon
terminals in response to synaptic activation (Mattson, 1994)where
it may play a role in neuronal maturation and synaptogenesis
(Priller et al., 2006).
Proliferation, migration, differentiation, myelination, and
synaptogenesis are all steps involved in generation of a mature
neuron. Some of the known functions of APP in these pro-
cesses include promotion of proliferation, cell–cell adhesion
(Schubert et al., 1989), migration (Mattson, 1994), and synap-
togenesis (Priller et al., 2006). More to the point, sAPPα has
speciﬁc activity in inducing cellular proliferation (Siemes et al.,
2004), including neural progenitor cells (Demars et al., 2011).
sAPPα facilitates substrate adhesion in cell culture (Wehner et al.,
2004). Induction of neuroprogenitor migration by sAPPα may
be due to sAPPα upregulation of C–C chemokine levels (Vrot-
sos and Sugaya, 2009). sAPPα induces synaptogenesis in response
to increases in ADAM10 (a disintegrin and metalloproteinase
domain-containing protein 10; α-secretase) levels (Bell et al.,
2008).
APP is predominantly located at synapses (Priller et al., 2006)
and is released from neurons in an activity-driven fashion (Matt-
son and Furukawa, 1998). mGluR type 1 and type 5 (mGluR1/5)
activation increases secretion of APP in cell culture (Jolly-Tornetta
et al., 1998). The expression of APP appears to be developmentally
controlled, with highest levels occurring early in synaptogenesis
(Priller et al., 2006). APP levels are higher post-natally rather than
prenatally but peak before 1 month of age in rodents (Lahiri et al.,
2002). APP plays a functional role during growth cone devel-
opment and has been implicated in neurite outgrowth (Mullan
and Crawford, 1993; Mattson and Furukawa, 1998). APP works
in opposition to NMDA (N-methyl-D-aspartate) and AMPA (α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors
with respect to glutamate’s pruning effects on growth cones (Matt-
son and Furukawa, 1998). Notably, APP blocks and reverses the
ability of glutamate to inhibit dendrite outgrowth in embryonic
rat hippocampal cell cultures (Mattson, 1994).
Knockdown of APP inhibits neuronal migration from the cor-
tical ventricular zone to the cortical plate in mice (Young-Pearse
et al., 2007). Conversely, overexpression of APP accelerates migra-
tion of neuronal precursor cells into the cortex (Young-Pearse
et al., 2007). In cell culture, APP has been linked to suppression
of neuronal cell adhesion (Schubert et al., 1989). Therefore, the
location of APP at the synapse and its developmental function in
migration and suppression of cell adhesion support the hypoth-
esis that dysregulated levels of APP contribute to unguided brain
growth as seen in autism (Courchesne et al., 2003). APP’s loca-
tion at synaptic dendrites, its regulation by translation repressors
such as FMRP, its participation in post-translational modiﬁ-
cation, and its role in neurogenesis and migration make it a
prime candidate to contribute to the synaptic disruption in
autism.
PROCESSING OF APP
Amyloid-β precursor protein is best known in association with
AD. Sequential cleavage of APP by the β-secretase, β-site APP
cleaving enzyme 1 (BACE1) and the γ-secretase complex (pre-
senilin 1, presenilin 2, nicastrin, anterior pharynx defective 1
homolog A, and other uncharacterized subunits) releases sAPPβ,
the APP intracellular domain (AICD) and amyloidogenic Aβ pep-
tide (Figure 1C), the major component of extracellular plaques
found in AD (Thinakaran and Koo, 2008).
Although APP-related research is generally in the context of
AD pathogenesis, the non-amyloidogenic (non-Aβ) “alpha” route
is actually the predominant pathway for APP processing (Postina,
2008). Its rate-limiting enzyme is theα-secretase family of “a disin-
tegrin and metalloprotease” (ADAM) proteins (ADAM9, 10, and
17; Deuss et al., 2008; Vingtdeux and Marambaud, 2012). In addi-
tion to potential “anti-pruning”activity, ADAM17 induces cellular
proliferation in a variety of conditions (Gooz et al., 2009; Lin et al.,
2012). Release of sAPPα is complete by the γ-secretase complex
(Lahiri et al., 2003; Thinakaran and Koo, 2008), along with the
non-amyloidogenic 3 kDa“p3”peptide and theAICD (Figure 1A).
sAPPα exhibits a wide array of neurotrophic activities (Matt-
son, 1997; Turner et al., 2003), important for neurodevelopment.
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sAPPα activates microglia, a function it shares with sAPPβ (Barger
and Harmon, 1997). In mice, sAPPα increases neurite outgrowth
and memory and protects against multiple insults (Stein and
Johnson, 2003). It has been suspected that APP contributes to
the predisposition to hematologic malignancy in Down syn-
drome patients and that APP aberration might predispose to
cancer (Morris et al., 2010). APP is among the most overexpressed
genes in acute myeloid leukemia patients with complex kary-
otypes (Baldus et al., 2004) and in solid tumors (Arvidsson et al.,
2008; Krause et al., 2008). Promotion of the non-amyloidogenic
pathway may be a promising novel treatment in AD (Bandy-
opadhyay et al., 2007). Recently, there has been interest in the
function of sAPPα in neurodevelopment and its relationship
to autism (Sokol et al., 2006) and FXS (Westmark and Malter,
2007). No speciﬁc tie has been found between p3 or AICD and
autism.
ADAM17 is also involved in the processing of tumor necrosis
TNF-α (tumor necrosis factor-alpha) at both the cell surface and
within the trans-Golgi network (Black et al., 1997). This process,
known as ”shedding,” involves cleavage and release of a soluble
ectodomain from membrane-bound pro-proteins (such as pro-
TNF-α), and is of known physiological importance (Black et al.,
1997), particularly in neoplastic proliferation (Xiao et al., 2012;
Zheng et al., 2012). While ADAM17 itself has not been speciﬁcally
studied in associationwith autism, the cerebrospinal ﬂuid to serum
ratio for TNF-α is elevated in subjects with autism compared to
other pathological states (Chez et al., 2007). Furthermore, linkage
was foundbetween a regionof humanchromosome2 that contains
the ADAM17 gene and autism (Allen-Brady et al., 2010).
GENETICS OF AUTISM
Twin studies, family studies, and predominately male distribution
of the disorder attest to theheritability of autism. Twin studies have
consistently shown thatmonozygotic twins areup to10 timesmore
likely to be concordant for autism than are dizygotic (Folstein and
Rutter, 1977; Steffenburg et al., 1989; Bailey et al., 1995). This rate
can be evaluated in comparison to other neurobiological disor-
ders such as AD, depression, bipolar disorder, and schizophrenia
(between 2:1 and 4:1), indicating a high heritability for autism
(Gatz et al., 2006; Pennington, 2009). However, the signiﬁcantly
earlier-life pathogenesis of autism vs. these other disorders means
that one cannot automatically exclude environmental “protective”
inﬂuences potentially reducing net genetic inﬂuence on heritabil-
ity in AD, schizophrenia, etc. Family studies (Piven and Palmer,
1999; Rutter,2000) suggest that the risk of autism is 20–60%higher
in siblings compared to in the general population. In addition, ﬁrst
degree relatives of individuals with autism were shown to be shy,
aloof, and have problematic pragmatic language (Rutter, 2000),
consistent with segregation of sub-threshold traits within these
families (Abrahams and Geschwind, 2008). These and other asso-
ciations have led to the deﬁnition of a “broad autism phenotype,”
which would suggest classifying autism as extreme manifestation
of a normal human variation (Sucksmith et al., 2011) rather than
inherently pathological in all its traits.
Autism affects more boys than girls (4:1), a ﬁnding that
has remained consistent since Kanner’s ﬁrst description in
1945, despite the increasing prevalence of its diagnosis. The
predominantly male ratio has been attributed to abnormality on
the X chromosome, or to sex linkage or genomic imprinting
(Marco and Skuse, 2006). However, such linkage has not been
found in all cases of autism, suggesting the importance of genetic
pathways other than the X chromosome. With rare exceptions,
however, autism does not appear to be the action of a single
gene inherited in a strictly Mendelian pattern, be it autosomal
dominant, autosomal recessive, or X-linked (O’Roak and State,
2008).
So-called “rare” genetic variants may contribute to autism
(Vorstman et al., 2006), although “rare” variants (disregarding
speciﬁc disease associations) are overall quite common, with
an estimated frequency of up to 3.4 such variants per per-
son (Nelson et al., 2012). Cytogenetic, gene association, linkage,
microarray technology, copy number variation (CNV) analysis
and exome sequencing lead to estimates of chromosomal abnor-
malities in autism that range from 6 to40% (Marshall et al., 2008;
Pennington, 2009; Abrahams and Geschwind, 2010). Chromo-
some regions associated with autism include chr2q37, chr7q22,
chr10q23, chr17q11-21, chr22q11, chr22q13, and chr15q11-13
(Sokol and Lahiri, 2011). Non-additive interaction among genes
(epistasis) has been proposed to account for such a large range
of chromosomal abnormality estimation (Poot et al., 2011; Ruzzo
et al., 2012). Of course, this leads to the inescapable question, what
accounts for the remaining 94–60% of autism not associated with
chromosomal abnormalities? While numerous studies identifying
candidate genes ormarkers have been reported, very few have been
replicated (Losh et al., 2008). One solution to this problem is to
study endophenotypes associated with autism (Duvall et al., 2007;
de Geus, 2010). None of the endophenotype studies has produced
a “deﬁnitive” solution. Instead of continuing down a single-cause
(DNA mutation) path, it may be more useful to presume that
autism is a complex disorder that depends upon interaction of
multiple levels of organization, not amenable to simple genetic
modeling.
BRAIN ABNORMALITY IN AUTISM: HISTOLOGY AND
POST-MORTEM ANATOMY
Little to no abnormality is revealed by standard hematoxylin and
eosin staining of autistic brain tissue (Casanova, 2007). Com-
plex assessment is necessary to reliably determine differences,
and research has required many samples to separate autistic
from controls. Post-mortem brain studies of autism have been
hindered by small sample sizes, with fewer than 150 autism
cases studied to date, the majority of them adults. Therefore,
the peak aberrant neurological growth identiﬁed by magnetic
resonance imaging (MRI) studies has not yet been conﬁrmed via
neuropathology (Schumann and Nordahl, 2011). Often, ﬁndings
cannot be repeated because the numbers of deaths is low in this
group, and death is often due to a cause that is likely to have an
effect on the histopathology, e. g., seizures.
These difﬁculties notwithstanding, in post-mortem studies, evi-
dence of autism-associated brain pathology includes disordered
interregional connectivity (Courchesne and Pierce, 2005), includ-
ing reduction in the size of the corpus callosum (Egaas et al.,
1995), minicolumn pathology (Casanova et al., 2006), deranged
neuronal development (Bauman and Kemper, 1985; van Kooten
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et al., 2008), and brain cytoarchitecture (Bauman and Kemper,
1985), and irregularity in brain structures associated with social
behavior (Stanﬁeld et al., 2008; Wegiel et al., 2010). Macrocephaly
is one of the most widely replicated biological ﬁndings in autism,
affecting up to 20% of children with the condition (Aylward
et al., 1999, 2002; McCaffery and Deutsch, 2005) and conﬁrmed
by MRI volumetric studies, described below (Piven et al., 1996;
Courchesne et al., 2001; Aylward et al., 2002; Sokol and Edwards-
Brown, 2004) and increased brain weight (Bauman and Kemper,
1985; Bailey et al., 1993). While occipital-frontal head circum-
ference (OFC) appears normal at birth, excessive brain growth
occurs early, around the time symptoms appear. Later growthmay
plateau or decline to normal circumference in adulthood (McCaf-
fery and Deutsch, 2005). Proposed mechanisms underlying brain
enlargement include overproduction of synapses, failure of synap-
tic pruning, excessive neurogenesis and gliogenesis, or reduction
in cell death (McCaffery and Deutsch, 2005)
Pathological studies of the frontal lobes of autistic brains,which
subserve social relatedness, the ability to change set, and the persis-
tence of repetitive behaviors, show increased microglial activation
(Vargas et al., 2005), and volume (Morgan et al., 2010), indicat-
ing potential neuroinﬂammation. Frontal lobe spindle neurons
(Schumann and Nordahl, 2011), showed no differences in adults
(Kennedy et al., 2007), but there was an increased ratio of spindle
neurons to pyramidal neurons in children (Santos et al., 2011). In
adults, a poorly deﬁned boundary was found at the frontal, pari-
etal, and temporal lobe gray-white matter junctions, suggestive of
abnormalities in neurogenesis or neuronal migration (Avino and
Hutsler, 2010).
Minicolumns, also known as microcolumns, are vertical
columns of neurons organized into pathways and intrinsic circuits
with a similar receptive ﬁeld (Buxhoeveden et al., 2001, 2006).
Casanova et al. (2002) found signiﬁcant differences between the
brains of autistic patients and controls in the number of mini-
columns, in the horizontal spacing that separates cell columns,
and in their internal structure. These ﬁndings have been essentially
replicated (Buxhoeveden et al., 2006; Casanova et al., 2006) and
indicate that excess proliferation of neurons early in development
is followed by a decrease in dendritic arborization, account-
ing for early overgrowth followed by normal brain volume in
autism (Schumann andNordahl, 2011). However, Casanova et al.’s
(2007) later comparison of the minicolumns of three internation-
ally distinguished neuroscientists vs. six non-scientist controls
showed a minicolumn pattern similar to what they found for
autism, although none of the scientists had reported autism-like
symptomology. This was explained by noting that narrower mini-
columns may favor discrimination and focused attention, two
traits necessary for scientiﬁc achievement. On the other hand,
autistic brains also have poorly synchronized and weak connec-
tivity between brain regions. For example weak connectivity has
been reported between the frontal cortex that supports decision
making, the left temporal lobe that supports speech, and right tem-
poral lobe that supports visual-spatial recognition (Courchesne
and Pierce, 2005). This may explain how individuals with autism
may lack facial recognition and have trouble verbally expressing
their ideas. Human APP and Drosophila equivalent APPL can
induce post-developmental axonal arborization in the Drosophila
CNS after brain damage (Leyssen et al., 2005). Further, APP has
been associated with neurogenesis and neuronal migration (Matt-
son and Furukawa, 1998). Of particular note, knockdown of APP
alters recruitment of interneurons in L5 and affects their laminar
distribution (Lodato et al., 2011), which would likewise alter orga-
nization and integration of neurons into functional neural circuits.
While sAPPα has not yet been studied in regard tomicrocolumnar
organization, amyloid-β deposits have been shown to contribute
to loss of microcolumnar organization (Buldyrev et al., 2000). APP
may play a role in neuronal network connectivity; it’s speciﬁc role
in minicolumn development remains to be determined.
There has been much work on neuropathology in the amyg-
dala, known to be involved with the perception of fear, anxiety,
and obsession-compulsion that would interfere with social rela-
tions. Kemper and Bauman (1993) found unusually small, densely
packed neurons in amygdale from older children and adults with
autismcompared to controls. SchumannandAmaral (2006) found
fewer neurons in the total amygdala but no increase in neu-
ronal density or decrease in the size of neurons from old children
and adults. It has been speculated that an excessive number of
neurons would be initially generated during early development
with their subsequent elimination during adulthood (Schumann
and Nordahl, 2011). This could explain inconsistent ﬁndings
between the neuropathology studies and the amygdala enlarge-
ment reported in the brain MRIs of younger children with autism
(Sparks et al., 2002; Schumann et al., 2004; Schumann andAmaral,
2006).
BRAIN ABNORMALITY IN AUTISM: FINDINGS FROM
MAGNETIC RESONANCE IMAGING
Brain MRI studies indicate that very young children with autism
(ages 18 months to 4 years) have a 5–10% abnormal enlargement
in total brain volume (Courchesne et al., 2001, 2003; Sparks et al.,
2002), although increased size of the adult brain also has been
reported (Piven et al., 1996). In addition, cross-sectional and lon-
gitudinal speciﬁc enlargement of the frontal and temporal lobes
has been found in 2 year olds with autism (Schumann et al., 2010),
and increased size of the adult brain also has been reported (Piven
et al., 1996). The amygdala also undergoes developmental enlarge-
ment in young boys with autism (Sparks et al., 2002; Schumann
et al., 2004) and later follows a growth trajectory different from
controls. A recent longitudinal study of 38 children with autism
and 21 controls showed enlargement of cortical volume (surface
area), but not cortical thickness at age two compared to ages 4
and 5 (Hazlett et al., 2011). Cortical surface area was linked to
the number of minicolumns in the cortical layer (Rakic, 1988),
while cortical thickness is thought to reﬂect dendritic arborization
(Huttenlocher and Hapke, 1990).
MECHANISMS OF APP IN AUTISM
We have previously reported high levels of total plasma sAPP
(including sAPPα) in a small sample of young children with
severe autism and aggression (Sokol et al., 2006). These children
expressed sAPP at two or more times the levels of children with-
out autism and up to four times more than children with mild
autism. Overall, there was a trend towards higher levels of both
sAPPα and total sAPP in children with autism, combined with a
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non-signiﬁcant decrease in Aβ40. This pointed toward the pos-
sibility of increased non-amyloidogenic (growth-promoting or
anabolic) processing in autism. These ﬁndings have been repli-
cated and extendedby an independent laboratory: Elevatedplasma
sAPPα was found in 60% of known autism children (n = 25)
compared to healthy age-matched controls (Bailey et al., 2008).
A recent follow up by our laboratory in a separate, larger set of
autismand control patient plasma samples (16 autism, 18 control),
conﬁrmed the original ﬁnding of signiﬁcantly elevated sAPPα in
plasma of severe autism patients, although without coexistant
aggression (Ray et al., 2011). Elevation in sAPPα was not found
with mild autism in either study. Crucially, this work showed
a decrease in levels of both Aβ40 and Aβ42 in severely autistic
patients compared to controls.
In summary,APP is regulated by FMRP via themGluR receptor
(Westmark and Malter, 2007). Functional consequences of exces-
sive mGluR signaling in absence of FMRP include prolongation of
epileptic formbursts in hippocampal areaCA3 (Bailey et al., 2008),
elongation of dendritic spines on cultured hippocampal neurons
(Vanderklish andEdelman,2002) and long-termdepression (LTD)
in hippocampal area CA1 (Li et al., 2007). These ﬁndings are asso-
ciated with the FXS clinical phenotypes: epilepsy, elongated and
immature dendritic spines, and cognitive delay, according to the
mGluR theory of FXS (Bear et al., 2004).
If mGluR5 signaling is enhanced in FXS individuals, excessive
APP translation would be expected, inevitably leading to higher
sAPPα levels. As evidence shows that excessive mGluR5 signals
favors an excitatory, anabolic state in FXS, we speculate that over-
expression of the mGlur5 pathway and resultant higher sAPPα
levels may likewise contribute to aggression, seizures, and intellec-
tual deﬁcit seen in severe autism. Further, it is hypothesized that
such anabolism may contribute to brain overgrowth associated
with autism.
One mechanism by which sAPPα could contribute to brain
overgrowth is by disrupting cell adhesion. Hazlett et al. (2011)
showed that early brain enlargement typical of autism may be
associated with increased surface area overgrowth due to faulty
cell adhesion. One such mechanism would be faulty adhesion
molecule β-catenin, a component of the cadherin protein com-
plex that constitutes adherens junctions. Adhesion molecules are
thought to reduce growth of brain progenitor cells. APP modu-
lates β-catenin degradation in vitro and in vivo (Chen and Bodles,
2007). Evidence also suggests that molecular defects in autism
interfere with synaptic protein synthesis (Kelleher and Bear, 2008).
Defects in translational repression would favor an anabolic state,
underlying the autistic phenotypes of macrocephaly, cognitive
impairment, and seizures.
APP AND FMRP
Protein synthesis is reduced in FXS, a rare neurodevelopmental
condition (1 in 4000males and 1 in 10,000 females; National Frag-
ile X Foundation, 2013), associated with intellectual disability, and
ASD in 2 in 3maleswith FXS (Hatton et al., 2006). FXS is caused by
a trinucleotide repeat (CGG repetitive sequence) in the promoter
region of the fragile X mental retardation 1 gene (FMR1). This
gene’s product, FMRP, is important for normal braindevelopment.
FMRP is an RNA binding and carrier protein that carries the
messages produced from many other genes to the synapse. FMRP
is involved in both activity-dependent transport of target mRNAs
and in regulation of local protein synthesis at the synapse (Bagni
and Greenough, 2005). Local protein synthesis following synaptic
activity is necessary formaintenance of some plastic changes at the
synapse and likely it is important for changes in spinemorphology
(Grossman et al., 2006). Therefore, FMRP-mediated regulation of
local protein synthesis is presumably essential for normal memory
and learning.
Fragile X mental retardation protein can be synthesized locally
in proximal dendrites (Feng et al., 1997), or recruited to the
synapse frommore distant sites after mGluR activation (De Diego
Otero et al., 2002). mGluR1/5 receptors are positioned in the post-
synaptic membrane, where they activate a Gq-coupled second
messenger system that transduces glutamate release into down-
stream phosphorylation cascades. Activation can lead to either
long-term potentiation (LTP) or LTD depending on cell type and
brain location. Activation of mGluR5 releases FMRP-mediated
translation repression and results in protein synthesis-dependent
LTD (Bear et al., 2004). Functional consequences of excessive
mGluR signaling in absence of FMRP include prolongation of
epileptic formbursts in hippocampal areaCA3 (Bailey et al., 2008),
elongation of dendritic spines on cultured hippocampal neurons
(Vanderklish and Edelman, 2002), and LTD in hippocampal area
CA1 (Li et al., 2007). These ﬁndings are associated with the FXS
clinical phenotypes: epilepsy, elongated, and immature dendritic
spines, and cognitive delay, according to the mGluR theory of FXS
(Bear et al., 2004).
In the resting state, FMRP binds to and inhibits dendritic trans-
lation of up to 4% of brain mRNAs including APP (De Rubeis
and Bagni, 2010). APP is regulated by FMRP via the mGluR
receptor (Westmark and Malter, 2007). If mGluR5 signaling is
enhanced in autistic individuals, excessive APP translation would
be expected, inevitably leading to higher sAPPα levels. Recently, we
found elevated sAPPα in the plasma of children with FXS (n = 18)
compared to typically developing, age-matched controls (n = 18;
Lahiri et al., 2011). Further, levels of Aβ40 and Aβ42 were higher
in FXS compared to controls (Lahiri et al., 2011). Preliminary evi-
dence for this same pattern, i.e., high levels of sAPPα and Aβ, was
found for a very small sample of left temporal lobe brain tissue
of FXS (n = 2) compared to typically developing, age-matched
control (n = 1). These results suggest investigating whether FXS
receives a “double dose” of deleterious components from non-
amyloidogenic and amyloidogenic pathways. Aβ40 andAβ42 levels
were signiﬁcantly higher in two strains of fmr-1 knockout mice
compared to wild type (Westmark and Malter, 2007). Genetic
downregulation of mGluR5 signaling has reversed behavioral
deﬁcits in fmr-1 knockout mice (Dolen et al., 2007; Dolen and
Bear, 2008). SimplemGluR5 antagonism, predicted to reduceAPP
via the anabolic pathway (Sokol et al., 2011), may reverse these
effects in humans.
APP IN THE Ras/ERK AND PI3K/Atk/mTOR PATHWAYS
The Ras small GTPase/extracellular signal-regulated kinase
(Ras/ERK) and phosphoinositide 3 kinase/protein kinase B/
mammalian target of rapamycin (PI3K/Akt/mTOR) signaling
pathways pair synaptic activity to the translational machinery and
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are also involved in protein synthesis-dependent LTP and LTD
(Kelleher and Bear, 2008). Mutation of the proteins which regulate
these pathways associateswith high prevalence of autism and intel-
lectual deﬁcit (Levitt and Campbell, 2009). Inactivatingmutations
of several negative regulators of the ERK and mTOR pathways,
such as neuroﬁbromin (neuroﬁbromatosis type 1), harmartin, and
tuberin (tuberous sclerosis), and PTEN (phosphatase and tensin
homolog) are responsible for genetic disorders with a high preva-
lence of cognitive impairment and autism (Levitt and Campbell,
2009). In the absence of functional proteins, these pathways are
“turned on” to excess. These signaling pathways are activated not
only by mGluR receptors, but also NMDA and neurotrophin Trk
receptors (Kelleher andBear,2008). Ras/ERK is activatedby sAPPα
(Demars et al., 2011), its secretaseADAM17 (Diaz-Rodriguez et al.,
2002), and neurotrophin Trk receptors. TrkB has the highest afﬁn-
ity to the binding of brain-derived neurotrophic factor (BDNF),
a growth factor with important roles in the survival and func-
tion of neurons and linked to both ASD and AD (Nickl-Jockschat
and Michel, 2011). Indeed, effects of acamprosate (N-acetyl-
homotaurine) on behavior and BDNF recently has been studied in
youth with FXS (Erickson et al., 2013). The researchers suggested
that the increasedBDNF levelswith treatmentmay serve as a useful
pharmacodynamic marker, which is consistent with the proposed
anabolic model. It would be interesting to test whether a change in
sAPPα levels could serve as another important pharmacodynamic
marker in neurodevelopmental disorders.
The PI3K/Akt/mTOR pathway is an FMRP-dependent path-
way (Narayanan et al., 2008). PTEN is a negative regulator of the
PI3K pathway. PTENmutation phenotypes include brain tumors,
macrocephaly, and autism (Butler et al., 2005; Kerr et al., 2006).
There is evidence that sAPPα, speciﬁcally, induces cellular pro-
liferation through the PI3K/mTOR pathway (Cheng et al., 2002),
and sAPPα activates Akt (Demars et al., 2011).
APP AND PROTEIN KINASE C
Reduced activity of protein kinase C (PKC) associates with regres-
sive autism (Ji et al., 2012). A linear relationship has been noted
between reduction in PKC activity and restricted, repetitive, and
stereotyped behaviors (Ji et al., 2012). Likewise, speciﬁc haplo-
types in the protein kinase c-β (PRKB1) gene are associated with
autism (Philippi et al., 2005). Protein phosphorylation by kinases
including PKC drives APP processing toward the anabolic α-
secretase pathway (Buxbaum et al., 1990; Caporaso et al., 1992).
This apparently contradicts the anabolic hypothesis and would
require further study.
THE UNIFYING EPIGENETIC LEARn MODEL IN AUTISM
Amyloid-β precursor protein’s role in FMRP, ERK, and mTOR
pathways is consistent with an overall, pro-growth, anti-apoptotic
role for APP. In a situation of nerve growth factor withdrawal,
Aβ production is upregulated, leading to neuronal apoptosis
(Matrone et al., 2008). In this way, APP activates both trophic
(through sAPPα) and apoptotic (through Aβ) pathways, and the
predominance of one may determine pathology: autism vs. AD.
The ﬁnding that the same gene can promote anabolism and
catabolism is reminiscent of FMRP’s role in FXS and Fragile
X-associated tremor/ataxia syndrome (FXTAS) found in subsets
of older adults harboring FMR1 premutations (Hagerman et al.,
2001). FXTAS is a condition of progressive tremor and ataxia in
individuals who show no pre-morbid cognitive deﬁcits, develop-
ing over the age of 50. Dementia occurs in a subset of those with
FXTAS. It is believed that FXS is caused by FMRP loss of function,
and FXTAS is caused by an FMR1mRNA gain of function toxicity
(Sokol et al., 2011). In the case of APP, loss of function would favor
the amyloidogenic pathway leading to AD while gain of function
toxicity would favor the non-amyloidogenic pathway leading to
excessive ADAM17, sAPPα, and brain overgrowth associated with
autism.
Autism is a complicated disorder for which many mod-
els combining genetic and external factors have been proposed
(Newschaffer et al., 2007; Abrahams and Geschwind, 2008; Pen-
nington, 2009). A key point of the anabolic hypothesis is that,
unlikemany geneticmodels, it is not a“change of function”model.
Genetic models based on coding sequence variation have gener-
ally presupposed that a pathogenic variant results in loss or gain of
function for a protein. The anabolic hypothesis, on the other hand,
does not propose qualitative differences in the activities of the par-
ticipating molecules. Instead, it is a quantitative model. Variation
in activity levels spells the difference between health and disorder.
Qualitative mutation in associated proteins could be informative,
particularly loss of function mutations, as these would effectively
mimic variations that result in atypically low levels of a protein
of interest. Likewise, gain of function mutations could essentially
mimic effects of atypically high levels of a protein, which permit a
minority function to reach a critical threshold.
Our basis for preferring an epigenetic explanation is a response
to dead ends and results from purely genetic models that fell very
far short of original expectations. Laying out matters plainly, no
genetic model has proved adequate to explain non-syndromic
autism, the condition’s most common form. Ever-ﬁner, ever-
broader GWAS or other genetic studies have repeatedly failed to
ﬁnd themagic target. As a result,models have had to resort to ever-
more Byzantine multi-gene invocations (Allen-Brady et al., 2009;
Anney et al., 2010).We propose an epigenetic model speciﬁcally in
the face of the failure of purely genetic presumptions, which may
have come to the point of invoking a “hidden variable” argument
analogous to those used by opponents of quantum physics.
Many of the proteins implicated in the anabolic hypothesis are
subject to or take part in epigenetic regulation. FMR1 has mul-
tiple phenotypes depending upon variable DNA methylation (de
Vries et al., 1996). Regulation of critical APP protein processing
enzymes was altered by changes in DNA methylation (Fuso et al.,
2005). ERK/mitogen-activated protein kinases (MAPK) signal-
ing activity drives epigenetic modiﬁcation that underlies stress,
learning, and memory processes (Trollope et al., 2012). It is now
accepted that epigenetic states can change after birth, including
by age-related drift (Martin, 2005) and speciﬁc changes associated
with late-life neurological disorders, such as AD (Poulsen et al.,
2007;Wang et al., 2008). Epigenetic changes can occur in response
to environmental stressors, such as exposure to heavy metals (Wu
et al., 2008) and famine (Hughes et al., 2009; Martin-Gronert and
Ozanne, 2010). Of particular interest is that these exposures can
have occurred in the previous generation, before conception, with
effects passed along to offspring (Flory et al., 2011).
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FIGURE 2 | sAPPα as a network activator in anabolic etiology of autism.
The sAPPα product has multiple functions that can contribute to neuronal
overgrowth and increase risk of autism. Speciﬁcally, sAPPα, produced by
α-secretase activity of proteins such as ADAM17, acts on its own as a cell
growth factor, stimulates neuronal migration, induces synaptogenesis, and
promotes cellular adhesion, all of which lead to neuroproliferation. In addition,
sAPPα activates ERK and Akt, which in turn also lead to neuroproliferation.
(A) Under normal development, these processes result in normal growth.
(B) sAPPα can contribute to anabolic etiology of autism through several
potential pathways, including overexpression of APP. Such overexpression
could be from derepression via FMRP deﬁciency, as in FXS. It must be
stressed that this is not the only possible cause of APP overexpression and is
cited simply as one of many potential examples. Increase in APP would lead
to greater sAPPα through the already dominant α-secretase pathway. This
would directly and indirectly lead to excess neuroproliferation through
multiple pathways, which would contribute to autism.
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In addition to the already-mentioned effect of DNA methyla-
tion status on FMR1-associated phenotypes (de Vries et al., 1996),
abnormal DNA methylation was found in the 5′-CpG island for
the UBE3A gene of autistic subjects (Jiang et al., 2004). The oxy-
tocin receptor gene has aberrant DNA methylation in its CpG
island, depending upon autism status (Gregory et al., 2009). These
speciﬁc differences were reﬂected in a wider scale across prefrontal
cortex neurons, which showed changes in chromatin structure at
multiple gene loci associated with neuronal connectivity, social
behaviors, and cognition, with altered levels of corresponding
transcripts (Shulha et al., 2012). Even the X chromosome associa-
tion explanation for the predominance ofmale autistic patients has
been questioned on epigenetic grounds. Speciﬁcally, sex hormone
activity mediates epigenetic modiﬁcations of DNA and histones,
increasing or decreasing risk of various diseases, such as autism
(Kaminsky et al., 2006).
Finally, to address the function of APP-in the anabolic hypoth-
esis, while evidence exists for levels of anabolic forms of APP (e.g.,
sAPPα) to contribute to autism, as we have outlined herein, no
speciﬁc genetic link has as of yet been reported in the literature.
We suggest that lack of discovery may be due to lack of presence.
A testable alternative hypothesis to explain APP’s role would be
epigenetic pathways.
Many workers have proposed that autism is a result of complex
interactionbetween genetic and environmental factors (Newschaf-
fer et al., 2007; Costa e Silva, 2008; Dufault et al., 2012). A speciﬁc,
testable expression of such concepts would be the LEARn model
(Lahiri et al., 2009; Maloney et al., 2012) in which complex neu-
rological disorders require multiple “hits” to clinically manifest.
Earlier hits would be latent epigeneticmarkers until sufﬁcient crit-
ical hits are accumulated by a necessary life span cutoff point, at
which time a disorder would become apparent. Should insufﬁ-
cient hits be suffered, or should hits be successfully detected and
remediated before the developmental threshold occurs, no disease
would appear.
In terms of autism, hits of interest could be those of early
post-natal development, particularly any that turned out to be
associated with DNA oxidation or DNA hypomethylation. These
two particular environmentally induced gene sequence lesions
have already been shown to be amenable to dietary remediation
by addition of S-adenosyl methionine, which resulted in rever-
sal of induced hypomethylation (Rogers et al., 2004; Chan and
Shea, 2006; Howard et al., 2011; Jousse et al., 2011). Likewise DNA
methylation status can be altered by social interaction, such as
differences in maternal care and rearing practices (Szyf, 2007;
Champagne and Curley, 2009; McGowan et al., 2009). LEARn-
informed research couldproduce rational relationships for therapy
and brain biochemistry in autism and early autistic conditions.
CONCLUSION
It is impossible to reduce ASDs to a direct, short-term etiology
or collection of simple factors. Instead, etiology of multiple path-
ways and gene products probably underlie the condition. This is
not to say that none of these could be critical. One such possible
fundamental target would be APP at the nexus of neuroprolifer-
ation and neural pruning and its interaction with networks such
as FMRP/mGluR, ERK/MAPK, and PI3K/mTOR (Figure 2). This
presents a possible handle upon autism etiology, should sAPPα
contribute to anabolic pathogenesis of the disorder. Of partic-
ular value is the evidence that APP dysfunction is more likely
due to environmental/epigenetic interaction rather than strict
genetic variation. Such dependency may permit environmental,
e.g., dietary, remediation, as mentioned herein, and possible
reversal at early stages of a disorder.
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